Pharmacological Characterization of Nanoparticle-induced Platelet Microaggregation Using Quartz Crystal Microbalance with Dissipation: Comparison with Light Aggregometry

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 Aug 29

PMID 26316743

Citations 8

Authors

Maria J Santos-Martinez

Krzysztof A Tomaszewski

Carlos Medina

Despina Bazou

John F Gilmer

Marek W Radomski

Affiliations

Soon will be listed here.

Abstract

Background: Engineered nanoparticles (NPs) can induce platelet activation and aggregation, but the mechanisms underlying these interactions are not well understood. This could be due in part to use of devices that study platelet function under quasi-static conditions with low sensitivity to measure platelet microaggregation. Therefore, in this study we investigated the pharmacological pathways and regulators of NP-induced platelet microaggregation under flow conditions at nanoscale using quartz crystal microbalance with dissipation (QCM-D) and compared the data thus obtained with those generated by light aggregometry.

Methods: Blood was collected from healthy volunteers, and platelet-rich plasma was obtained. Thrombin receptor-activating peptide, a potent stimulator of platelet function, and pharmacological inhibitors were used to modulate platelet microaggregation in the presence/absence of silica (10 nm and 50 nm) and polystyrene (23 nm) NPs. Light aggregometry was used to study platelet aggregation in macroscale. Optical, immunofluorescence, and scanning electron microscopy were also used to visualize platelet aggregates.

Results: Platelet microaggregation was enhanced by thrombin receptor-activating peptide, whereas prostacyclin, nitric oxide donors, acetylsalicylic acid, and phenanthroline, but not adenosine diphosphate (ADP) blockers, were able to inhibit platelet microaggregation. NPs caused platelet microaggregation, an effect not detectable by light aggregometry. NP-induced microaggregation was attenuated by platelet inhibitors.

Conclusion: NP-induced platelet microaggregation appears to involve classical proaggregatory pathways (thromboxane A2-mediated and matrix metalloproteinase-2-mediated) and can be regulated by endogenous (prostacyclin) and pharmacological (acetylsalicylic acid, phenanthroline, and nitric oxide donors) inhibitors of platelet function. Quartz crystal microbalance with dissipation, but not light aggregometry, is an appropriate method for studying NP-induced microaggregation.

Citing Articles

High-Capacity Mesoporous Silica Nanocarriers of siRNA for Applications in Retinal Delivery.

Ultimo A, Orzaez M, Santos-Martinez M, Martinez-Manez R, Marcos M, Sancenon F Int J Mol Sci. 2023; 24(3).

PMID: 36769075 PMC: 9916966. DOI: 10.3390/ijms24032753.

Aluminum Nanoparticles Affect Human Platelet Function In Vitro.

Taterra D, Skinningsrud B, Lauritzen S, Pekala P, Szwedowski D, Tomaszewska I Int J Mol Sci. 2023; 24(3).

PMID: 36768869 PMC: 9916829. DOI: 10.3390/ijms24032547.

Magnetic Platelets as a Platform for Drug Delivery and Cell Trapping.

Mayorova O, Gusliakova O, Prikhozhdenko E, Verkhovskii R, Bratashov D Pharmaceutics. 2023; 15(1).

PMID: 36678843 PMC: 9866132. DOI: 10.3390/pharmaceutics15010214.

Ethyl Hydroxyethyl Cellulose-A Biocompatible Polymer Carrier in Blood.

Eckelt A, Wichmann F, Bayer F, Eckelt J, Gross J, Opatz T Int J Mol Sci. 2022; 23(12).

PMID: 35742876 PMC: 9223706. DOI: 10.3390/ijms23126432.

Effect on Platelet Function of Metal-Based Nanoparticles Developed for Medical Applications.

Hante N, Medina C, Santos-Martinez M Front Cardiovasc Med. 2019; 6:139.

PMID: 31620449 PMC: 6759469. DOI: 10.3389/fcvm.2019.00139.

References

Radomski M, Palmer R, Moncada S . Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987; 2(8567):1057-8. DOI: 10.1016/s0140-6736(87)91481-4. View

Radomski M, Palmer R, Moncada S . Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987; 92(1):181-7. PMC: 1853617. DOI: 10.1111/j.1476-5381.1987.tb11310.x. View

Radomski M, Palmer R, Moncada S . An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990; 87(13):5193-7. PMC: 54288. DOI: 10.1073/pnas.87.13.5193. View

Radomski M, Rees D, Dutra A, Moncada S . S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 1992; 107(3):745-9. PMC: 1907743. DOI: 10.1111/j.1476-5381.1992.tb14517.x. View

Salas E, Moro M, Askew S, HODSON H, Butler A, Radomski M . Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets. Br J Pharmacol. 1994; 112(4):1071-6. PMC: 1910248. DOI: 10.1111/j.1476-5381.1994.tb13192.x. View

Moro M, Russel R, Cellek S, Lizasoain I, Su Y, Darley-Usmar V . cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996; 93(4):1480-5. PMC: 39965. DOI: 10.1073/pnas.93.4.1480. View

Corbalan J, Medina C, Jacoby A, Malinski T, Radomski M . Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. Int J Nanomedicine. 2012; 7:631-9. PMC: 3278227. DOI: 10.2147/IJN.S28293. View

Lesniak A, Salvati A, Santos-Martinez M, Radomski M, Dawson K, Aberg C . Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc. 2013; 135(4):1438-44. DOI: 10.1021/ja309812z. View

Hennekens C, Dalen J . Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med. 2013; 126(5):373-8. DOI: 10.1016/j.amjmed.2012.12.013. View

10.

Youssef A, Kamel S, El-Samahy M . Morphological and antibacterial properties of modified paper by PS nanocomposites for packaging applications. Carbohydr Polym. 2013; 98(1):1166-72. DOI: 10.1016/j.carbpol.2013.06.059. View

11.

Gliga A, Skoglund S, Odnevall Wallinder I, Fadeel B, Karlsson H . Size-dependent cytotoxicity of silver nanoparticles in human lung cells: the role of cellular uptake, agglomeration and Ag release. Part Fibre Toxicol. 2014; 11:11. PMC: 3933429. DOI: 10.1186/1743-8977-11-11. View

12.

Santos-Martinez M, Rahme K, Corbalan J, Faulkner C, Holmes J, Tajber L . Pegylation increases platelet biocompatibility of gold nanoparticles. J Biomed Nanotechnol. 2014; 10(6):1004-15. DOI: 10.1166/jbn.2014.1813. View

13.

Khan I, Serra C, Anton N, Vandamme T . Production of nanoparticle drug delivery systems with microfluidics tools. Expert Opin Drug Deliv. 2014; 12(4):547-62. DOI: 10.1517/17425247.2015.974547. View

14.

Tomaszewski K, Radomski M, Santos-Martinez M . Nanodiagnostics, nanopharmacology and nanotoxicology of platelet-vessel wall interactions. Nanomedicine (Lond). 2015; 10(9):1451-75. DOI: 10.2217/nnm.14.232. View

15.

Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I . Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res. 2001; 61(1):376-82. View

16.

. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71-86. PMC: 64503. DOI: 10.1136/bmj.324.7329.71. View

17.

Nemmar A, Hoet P, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts M . Passage of inhaled particles into the blood circulation in humans. Circulation. 2002; 105(4):411-4. DOI: 10.1161/hc0402.104118. View

18.

Egashira K . Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J. 2002; 66(6):529-33. DOI: 10.1253/circj.66.529. View

19.

Ruggeri Z . Platelets in atherothrombosis. Nat Med. 2002; 8(11):1227-34. DOI: 10.1038/nm1102-1227. View

20.

Sawicki G, Salas E, MURAT J, Radomski M . Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997; 386(6625):616-9. DOI: 10.1038/386616a0. View